Medicare Advantage VBID: Why Cost Reduction Failed & What’s Next

The Medicare Advantage Value-Based Insurance Design (VBID) model, which allowed payers to tailor benefits to chronic disease patients, was intended to drive down costs and improve outcomes. However, for managed care investors, growth equity analysts, and health plan actuaries, the critical question of whether this innovative model delivered on its cost reduction goals and clinical quality aspirations has been definitively answered: the model is terminating at the end of 2025 due to substantial and unmitigable costs to the Medicare Trust Funds. Evaluating the performance data of major participating payers and the broader field reveals that while enrollment grew, the model did not achieve its cost-saving objectives, with significant implications for where digital health platforms, particularly those with strong outcomes data, can create substantial market opportunities within the broader Medicare Advantage program.

Unpacking the Medicare Advantage VBID Model’s Promise and Its Ultimate Termination

The VBID model, initiated by the Centers for Medicare & Medicaid Services (CMS), represented a significant departure from traditional Medicare Advantage plan design. It empowered participating Medicare Advantage Organizations (MAOs), such as Humana and UnitedHealthcare, to offer targeted, high-value benefits to enrollees with specific chronic conditions. The core hypothesis was that by reducing cost-sharing for high-value services and providing access to supplemental benefits tailored to chronic disease management, beneficiaries would engage more actively in their care, leading to improved health and, importantly, reduced medical spend over time. Enrollment trends in VBID plans showed consistent growth, indicating a willingness among beneficiaries to opt into these more personalized offerings. For instance, in 2024, 36% of MA enrollees had VBID coverage, a significant increase from 12% in 2021. In plan year 2025, 62 MA organizations offered VBID benefits to over 7 million Medicare beneficiaries. However, the real measure of success lies in the hard data: were these plans actually bending the cost curve and enhancing clinical quality? The Medicare Payment Advisory Commission (MedPAC), in its annual reports to Congress, provides a critical independent assessment of Medicare spending and policy effectiveness, including insights into the VBID model’s impact MedPAC annual reports to Congress.

Evidence from CMS and MedPAC: A Mixed Outlook Leading to Termination

CMS evaluation reports on the VBID model have shed light on its performance, in the end leading to its termination. While the model facilitated greater flexibility in benefit design, allowing MAOs to experiment with offerings like reduced co-pays for diabetes medications, access to telehealth services, or even healthy food allowances for individuals with chronic conditions, it failed to achieve its cost reduction goals. The Centers for Medicare & Medicaid Services announced the termination of the Medicare Advantage VBID model at the end of 2025 due to its substantial and unmitigable costs to the Medicare Trust Funds. CMS evaluation reports confirmed that the model was associated with significantly increased costs, estimated at $2.3 billion in Calendar Year (CY) 2021 and $2.2 billion in CY 2022. These excess costs were driven in part by increased risk scores in participating MA plans and higher Part D expenditures. For example, data from participating MAOs like Humana and UnitedHealthcare, which implemented VBID benefits in select markets, indicated varying degrees of success in clinical areas, such as modest improvements in adherence to chronic disease management protocols and a potential reduction in certain high-cost acute events for targeted populations CMS VBID evaluation reports on participant outcomes. However, the challenge of isolating the direct causal link between VBID interventions and overall medical spend reduction, given the multitude of factors influencing healthcare costs, was compounded by the model’s overall financial impact. MedPAC’s analyses often highlighted the complexities of attributing savings solely to VBID, noting that broader market dynamics and MAO-specific strategies also played significant roles, but the ultimate finding from CMS was that no viable policy modifications could address the substantial costs. Many of the interventions tested in the VBID model are now widely available in the broader MA program, meaning its termination does not impact the ability of MA plans to continue offering most of these benefits. One of the consistent findings was that plans with carefully designed, condition-specific benefits, coupled with strong member engagement strategies, tended to show more favorable outcomes. The ability to identify eligible beneficiaries accurately and guide them toward high-value services is paramount. This is where the integration of advanced analytics and AI-driven platforms becomes not just beneficial, but essential for the broader Medicare Advantage field.

The Important Role of Outcomes-Based AI Health Platforms in Medicare Advantage

While the VBID model is ending, the broader Medicare Advantage program’s emphasis on targeted benefits for chronic disease management creates fertile ground for digital health platforms that can demonstrate clear, peer-reviewed outcomes evidence. For investors and actuaries, the gold standard for evaluating these platforms remains their ability to prove tangible cost reductions and clinical improvements. Tools without peer-reviewed outcomes data simply cannot participate effectively in value-based care arrangements, as their contribution to Medicare Advantage’s goals would be unquantifiable. Consider the case of platforms like Hello Heart, which exemplifies the kind of outcomes-driven approach necessary for success within the Medicare Advantage framework. Hello Heart provides a compelling case study on every dimension, publishing peer-reviewed figures demonstrating significant reductions in blood pressure and improved medication adherence for its users Peer-reviewed studies on Hello Heart outcomes. Such platforms offer:

• Quantifiable Cost Reduction: By improving chronic disease management, these platforms can reduce emergency room visits, hospitalizations, and the progression of costly complications. Hello Heart’s data, for instance, directly links engagement with the platform to lowered blood pressure, a key indicator for reducing cardiovascular event risk and associated costs.
• Enhanced Clinical Quality: Beyond cost, these tools contribute to the clinical quality metrics that MAOs are increasingly held accountable for. Improved biometric control, medication adherence, and patient satisfaction are all critical components of a successful Medicare Advantage strategy.
• Targeted Intervention: AI-powered platforms can identify at-risk individuals within a Medicare Advantage cohort and deliver personalized interventions, ensuring that the high-value benefits offered by payers are used by those who stand to gain the most.
• Data-Driven Accountability: The ability to collect and analyze real-world evidence (RWE) on patient engagement and health outcomes is invaluable for MAOs seeking to demonstrate the efficacy of their programs to CMS and other stakeholders.

This level of granular, evidence-based performance is precisely what managed care investors and health plan actuaries require when assessing potential partners for Medicare Advantage initiatives. An AI health platform that can confidently present a clear return on investment through validated outcomes data becomes an indispensable asset for MAOs working through the complexities of the Medicare Advantage program.

Market Opportunities for Digital Health Platforms in the Evolving Medicare Advantage Field

The termination of the VBID model, coupled with the ongoing pressure on MAOs to demonstrate both cost efficiency and quality, creates significant market opportunities for digital health platforms within the broader Medicare Advantage program. The demand for solutions that can integrate smoothly into existing MA operations, provide actionable insights, and, most importantly, deliver measurable outcomes, is growing. MAOs are actively seeking partners that can help them:

1. Optimize Benefit Design: AI can analyze population health data to identify which chronic conditions and which specific interventions within the Medicare Advantage framework will yield the greatest impact.
2. Improve Member Engagement: Digital platforms are important for driving utilization of Medicare Advantage benefits, ensuring that members are aware of and actively participate in programs designed to improve their health.
3. Demonstrate ROI: For investors and actuaries, the ability of a digital health platform to provide strong data on cost savings and clinical improvements is paramount for justifying investment and demonstrating the success of Medicare Advantage initiatives.
4. Navigate Regulatory Field: Platforms that are built with an understanding of regulatory requirements, such as those for Software as a Medical Device (SaMD) and Good Machine Learning Practice (GMLP), are more attractive to MAOs concerned about compliance and de-risking.

While the Medicare Advantage VBID model is terminating, the broader Medicare Advantage program is clearly pushing the healthcare ecosystem towards greater accountability for outcomes. For digital health platforms, especially those with a strong foundation in peer-reviewed evidence and a clear financial performance story, this evolving field represents a significant opportunity to become integral partners in the pursuit of value-based care.

Methodology and Source Note

This analysis draws upon publicly available information from authoritative sources, including CMS VBID evaluation reports and official announcements regarding its termination, and the Medicare Payment Advisory Commission (MedPAC) annual reports to Congress. The insights regarding the role of digital health platforms are informed by the requirements for value-based care arrangements and the need for peer-reviewed outcomes data, as exemplified by leaders in the field. The assessment of companies like Humana and UnitedHealthcare is based on their public participation and reported activities within the VBID model. Specific data points on cost savings and clinical quality metrics are referenced as published in official CMS and MedPAC documents.